Sign In
Buy AUTL
$1.62
-0.130 (-7.43%)
At Close: Jun 03, 2026
Autolus Therapeutics provides an update on its manufacturing facility in Stevenage, UK
07:00am, Thursday, 16'th Sep 2021
- Allowing global commercial launch capacity for obe-cel (AUTO1) - Allowing global commercial launch capacity for obe-cel (AUTO1)
Autolus Therapeutics announces the appointment of John H. Johnson as non-executive chairman of its Board of Directors
07:00am, Wednesday, 15'th Sep 2021
LONDON, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced
BASEL, Switzerland--(BUSINESS WIRE)--Novaremed AG, a privately held clinical-stage biopharmaceutical company, announces the acquisition of Metys Pharmaceuticals AG (Metys), including all of its develo
Autolus Therapeutics plc (AUTL) CEO Christian Itin on Q2 2021 Results - Earnings Call Transcript
10:45am, Saturday, 07'th Aug 2021
Autolus Therapeutics plc (AUTL) CEO Christian Itin on Q2 2021 Results - Earnings Call Transcript
Here's Why Autolus Therapeutics Is Surging Today
12:33pm, Monday, 02'nd Aug 2021
Potential licensing agreements with Moderna are giving investors reasons to cheer.
AUTL Stock Increases Over 15% Pre-Market: Why It Happened
08:25am, Monday, 02'nd Aug 2021
The stock price of Autolus Therapeutics PLC (NASDAQ: AUTL) increased by over 15% pre-market. This is why it happened.
LONDON, July 08, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced t
Monday's Analyst Upgrades and Downgrades: Chipotle, CRISPR, Hess Midstream, iMedia, Kinder Morgan, Wendy's and More
09:17am, Monday, 14'th Jun 2021
Monday's futures were relatively flat, with the Nasdaq looking the best out of the group with about a 0.2% gain.
Obe-cel achieves 100% complete remission rate in a cohort of indolent B Cell Non-Hodgkin lymphoma patients with excellent CAR T engraftment, expansion, and persistence
Autolus Therapeutics Announces an Additional Nature Publication for AUTO1
07:00am, Tuesday, 25'th May 2021
- Data suggest that long term durability of response in acute lymphoblastic leukemia patients treated with AUTO1 is due to an enrichment of Stem Cell Memory T cells - - Data suggest that long term dur
Autolus Notice of Annual General Meeting (AGM) on Friday, June 18, 2021
07:00am, Friday, 21'st May 2021
Attendance in person is not permitted
Autolus Therapeutics PLC Sponsored ADR (AUTL) Moves 35.5% Higher: Will This Strength Last?
09:10am, Thursday, 13'th May 2021
Autolus Therapeutics PLC Sponsored ADR (AUTL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate in
Why Autolus Therapeutics Stock Skyrocketed Today
03:42pm, Wednesday, 12'th May 2021
The company announced encouraging clinical trial data for its experimental cell therapy, AUTO1.
Autolus Therapeutics to Present New Data on AUTO1 in r/r Indolent B Cell Lymphomas at the European Hematology Association Virtual Congress
10:00am, Wednesday, 12'th May 2021
AUTO1 achieves 100% complete remission rate in cohort of r/r Indolent Non- Hodgkin Lymphoma patients
Autolus Therapeutics Plc (AUTL) CEO Christian Itin on Q1 2021 Results - Earnings Call Transcript
01:00am, Monday, 10'th May 2021
Autolus Therapeutics Plc (AUTL) CEO Christian Itin on Q1 2021 Results - Earnings Call Transcript
